Dual high expression of STAT3 and cyclinD1 is associated with poor prognosis after curative resection of esophageal squamous cell carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 11, 2014, Pages 7989-7998

  Li, Haiying ^a,b   Xiao, Weiwei ^c   Ma, Jiwei ^a,b   Zhang, Yong ^a,b   Li, Ru ^a,b   Ye, Jiecheng ^a,b   Wang, Xiao ^a   Zhong, Xueyun ^a,b   Wang, Shaoxiang ^d  

^a JINAN UNIVERSITY   (China)

^b MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d SHENZHEN UNIVERSITY   (China)

Author keywords

CyclinD1; Esophageal squamous cell carcinoma; Immunohistochemistry; Prognosis; Signal transducer of activator of transcription 3

Indexed keywords

CYCLIN D1; STAT3 PROTEIN;

ADULT; AGED; CANCER GRADING; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CYCLIN D1; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; STAT3 TRANSCRIPTION FACTOR; SURVIVAL RATE;

EID: 84919466425     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Zeng R, Duan L, Kong Y, Liang Y, Wu X, Wei X, Yang K. Clinicopathological and prognostic role of MMP-9 in esophageal squamous cell carcinoma: a meta-analysis. Chin J Cancer Res 2013; 25: 637-645.
2. Lam TK, Freedman ND, Fan JH, Qiao YL, Dawsey SM, Taylor PR, Abnet CC. Prediagnostic plasma vitamin C and risk of gastric adenocarcinoma and esophageal squamous cell carcinoma in a Chinese population. Am J Clin Nutr 2013; 98: 1289-1297.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
4. Chen JW, Xie JD, Ling YH, Li P, Yan SM, Xi SY, Luo RZ, Yun JP, Xie D, Cai MY. The prognostic effect of perineural invasion in esophageal squamous cell carcinoma. BMC Cancer 2014; 14: 313.
5. Darnell JE Jr. STATs and gene regulation. Science 1997; 277: 1630-1635.
6. Xiong A, Yang Z, Shen Y, Zhou J, Shen Q. Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention. Cancers (Basel) 2014; 6: 926-957.
7. Lee SW, Ahn YY, Kim YS, Kang SB, Nam SW, Lee DS, Jeong HY, Kim JM. The Immunohistochemical Expression of STAT3, Bcl-xL, and MMP-2 Proteins in Colon Adenoma and Adenocarcinoma. Gut Liver 2012; 6: 45-51.
8. Bishop JL, Thaper D, Zoubeidi A. The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer. Cancers (Basel) 2014; 6: 829-859.
9. Wang Y, Zhu JF, Liu YY, Han GP. An analysis of cyclin D1, cytokeratin 5/6 and cytokeratin 8/18 expression in breast papillomas and papillary carcinomas. Diagn Pathol 2013; 8: 8.
10. Seiler R, Thalmann GN, Rotzer D, Perren A, Fleischmann A. CCND1/CyclinD1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response. Mod Pathol 2014; 27: 87-95.
11. Umekita Y, Ohi Y, Sagara Y, Yoshida H. Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer 2002; 98: 415-418.
12. Gagarin D, Yang Z, Butler J, Wimmer M, Du B, Cahan P, McCaffrey TA. Genomic profiling of acquired resistance to apoptosis in cells derived from human atherosclerotic lesions: potential role of STATs, cyclinD1, BAD, and Bcl-XL. J Mo Cell Cardiol 2005; 39: 453-465.
13. Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer 2000; 88: 2887.
14. Gao H, Wang L, Cui S, Wang M. Combination of meta-analysis and graph clustering to identify prognostic markers of ESCC. Genet Mol Biol 2012; 35: 530-537.
15. Kato K, Hida Y, Miyamoto M, Hashida H, Shinohara T, Itoh T, Okushiba S, Kondo S, Katoh H. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 2002; 94: 929-933.
16. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 Suppl 8: S4-66.
17. Koshy M, Esiashvilli N, Landry JC, Thomas CR Jr, Matthews RH. Multiple management modalities in esophageal cancer: combined modality management approaches. Oncologist 2004; 9: 147-159.
18. Lin DC, Du XL, Wang MR. Protein alterations in ESCC and clinical implications: a review. Dis Esophagus 2009; 22: 9-20.
19. Ashida A, Boku N, Aoyagi K, Sato H, Tsubosa Y, Minashi K, Muto M, Ohtsu A, Ochiai A, Yoshida T. Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications. Int J Oncol 2006; 28: 1345-1352.
20. Ihle JN. STATs and MAPKs: obligate or opportunistic partners in signaling. Bioessays 1996; 18: 95-98.
21. Ai T, Wang Z, Zhang M, Zhang L, Wang N, Li W, Song L. Expression and prognostic relevance of STAT3 and cyclin D1 in non-small cell lung cancer. Int J Biol Markers 2012; 27: e132-138.
22. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, Tweardy DJ. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J Clin Invest 1998; 102: 1385-1392.
23. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-115.
24. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002; 8: 945-954.
25. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001; 107: 351-362.
26. Barton BE, Murphy TF, Adem P, Watson RA, Irwin RJ, Huang HF. IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells. BMC Cancer 2001; 1: 19.
27. Bournazou E, Bromberg J. Targeting the tumor microenvironment: JAK-STAT3 signaling. JAKSTAT 2013; 2: e23828.
28. Wang C, Li Z, Lu Y, Du R, Katiyar S, Yang J, Fu M, Leader JE, Quong A, Novikoff PM. Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function. Proc Natl Acad Sci U S A 2006; 103: 11567-11572.
29. Sakamaki T, Casimiro MC, Ju X, Quong AA, Katiyar S, Liu M, Jiao X, Li A, Zhang X, Lu Y. Cyclin D1 determines mitochondrial function in vivo. Mol Cell Biol 2006; 26: 5449-5469.
30. Wang C, Pattabiraman N, Zhou JN, Fu M, Sakamaki T, Albanese C, Li Z, Wu K, Hulit J, Neumeister P. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol 2003; 23: 6159-6173.
31. Yasui M, Yamamoto H, Ngan CY, Damdinsuren B, Sugita Y, Fukunaga H, Gu J, Maeda M, Takemasa I, Ikeda M. Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumor vascularization. Clin Can Res 2006; 12: 4720-4729.
32. Li Z, Wang C, Prendergast GC, Pestell RG. Cyclin D1 functions in cell migration. Cell Cycle 2006; 5: 2440-2442.
33. Huang C, Yang G, Jiang T, Cao J, Huang KJ, Qiu ZJ. Down-regulation of STAT3 expression by vector-based small interfering RNA inhibits pancreatic cancer growth. World J Gastroenterol 2011; 17: 2992-3001.
34. Xu Y, Shi Y, Yuan Q, Liu X, Yan B, Chen L, Tao Y, Cao Y. Epstein-Barr Virus encoded LMP1 regulates cyclin D1 promoter activity by nuclear EGFR and STAT3 in CNE1 cells. J Exp Clin Cancer Res 2013; 32: 90.
35. Saxena NK, Vertino PM, Anania FA, Sharma D. Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J Biol Chem 2007; 282: 13316-13325.
36. Won C, Lee CS, Lee JK, Kim TJ, Lee KH, Yang YM, Kim YN, Ye SK, Chung MH. CADPE suppresses cyclin D1 expression in hepatocellular carcinoma by blocking IL-6-induced STAT3 activation. Anticancer Res 2010; 30: 481-488.